The immunosuppressant leflunomide blocks the yeast Saccharomyces cerevisiae cell cycle at the G1 phase.
Leflunomide is a novel immunomodulatory drug representing a new small molecule class of substances which are structurally unrelated to previously described immunomodulatory/immunosuppressive compounds. The effect of leflunomide on the cell cycle of Saccharomyces cerevisiae was investigated to elucidate the molecular mechanism of its action in eukaryotic organisms. When yeast cells were treated with leflunomide, unbudded cells were accumulated, suggesting that leflunomide may arrest the cell cycle in the G1 phase. When leflunomide-treated cells were subjected to heat shock treatment, the cells became resistant to heat shock treatment, implying that leflunomide-mediated block to cell division results in entry from the proliferative cycle into the alternative developmental G0 phase.
Fujimura
H
H
Central Research Laboratory, Nippon Hoechst Mrion Roussel, Kawagoe, Japan.
D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004352:Drug Resistance, Microbial / Q000235:genetics; D016193:G1 Phase / Q000187:drug effects; D006358:Hot Temperature; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007555:Isoxazoles / Q000494:pharmacology*; D000077339:Leflunomide; D009154:Mutation; D012441:Saccharomyces cerevisiae / Q000166:cytology / Q000187:drug effects* / Q000235:genetics
D007166:Immunosuppressive Agents; D007555:Isoxazoles; D000077339:Leflunomide